Advertisement
MTD vs SYK
Which Stock Would AI Choose? Mettler-Toledo International (MTD) vs. Stryker Corporation (SYK) Stock Comparison
Key Takeaways
- Mettler-Toledo International (MTD) and Stryker Corporation (SYK) operate in adjacent but distinct segments of the life sciences and medical technology industries, with MTD focused on precision instruments and SYK on orthopedic and surgical equipment.
- MTD has faced headwinds from a slower-than-expected recovery in China and broader industrial demand softness, while SYK has benefited from sustained procedural volume growth and a robust product pipeline.
- Both companies maintain strong competitive moats, though their growth drivers diverge significantly: MTD relies on laboratory and industrial capex cycles, whereas SYK is tied to hospital capital spending and elective surgery trends.
- Market sentiment has tilted more favorably toward SYK in recent months, reflecting stronger earnings consistency and clearer near-term catalysts in the medtech space.
- From an AI-driven analytical standpoint, trend consistency and momentum indicators currently favor one of these two names, though the divergence may narrow depending on macroeconomic developments.
Introduction
For investors evaluating opportunities at the intersection of healthcare, technology, and precision manufacturing, MTD and SYK represent two compelling but fundamentally different plays. Mettler-Toledo International is a global leader in precision instruments and weighing solutions for laboratories, industrial applications, and food retail. Stryker Corporation, by contrast, is a medical technology powerhouse specializing in orthopedic implants, surgical equipment, and neurotechnology. This comparison is particularly relevant for those seeking to understand how capital-equipment-oriented and procedure-driven business models perform under current macroeconomic conditions, and which might align better with prevailing market trends.
MTD Overview and Recent Performance
MTD, or Mettler-Toledo International, derives the majority of its revenue from laboratory instruments (such as analytical balances, titrators, and thermal analysis systems), along with industrial weighing and inspection solutions. In recent weeks, MTD has navigated a challenging demand environment, particularly in China, where a slower-than-anticipated post-pandemic recovery has weighed on laboratory instrument orders. The company's exposure to pharmaceutical and life sciences capital expenditure cycles has also introduced some cyclical pressure. Despite these headwinds, MTD continues to generate strong free cash flow and maintains a disciplined capital allocation strategy, including consistent share repurchases. The stock has experienced choppy trading in recent market activity, with investors reassessing the pace of a potential demand recovery in the second half of the year. Margin resilience has remained a bright spot, supported by pricing discipline and operational efficiency initiatives.
SYK Overview and Recent Performance
SYK, or Stryker Corporation, is one of the largest pure-play medical device companies globally, with leading positions in orthopedics (joint replacements, trauma, and spine), MedSurg (surgical equipment, endoscopy, and emergency medical services), and neurotechnology (neurovascular and craniomaxillofacial products). In recent months, SYK has benefited from elevated surgical procedure volumes, driven by an aging population and the ongoing normalization of elective surgeries post-pandemic. The company's Mako robotic-assisted surgery platform continues to gain adoption, reinforcing its competitive moat in joint replacement. Recent quarterly results have reflected robust organic revenue growth across most segments, and the stock has generally outperformed the broader medtech peer group. Analysts have noted SYK's ability to sustain pricing power and expand operating margins even amid cost inflation, supporting a relatively premium valuation multiple. Market sentiment around SYK has remained constructive, grounded in visible revenue catalysts and a diversified portfolio that reduces single-segment dependency.
Trending AI Robots
For traders and investors seeking a data-driven edge in evaluating stocks like MTD and SYK, Tickeron's Trending AI Robots offers a curated selection of AI-powered trading bots designed to navigate evolving market conditions. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each employing distinct strategies — ranging from swing trading and trend following to pattern recognition and momentum-based approaches. Only the most consistently effective bots, those best suited to current market dynamics, earn a spot in the Trending AI Robots section. Many of these bots feature documented win rates, statistical track records, and real-time performance metrics that allow users to assess their historical consistency. With varied timeframes, risk profiles, and asset coverage, the platform provides transparency into how artificial intelligence interprets market signals across different trading styles. Explore the Trending AI Robots to discover which automated strategies are currently resonating with market conditions.
Head-to-Head Comparison
When placing MTD and SYK side by side, several key contrasts emerge. From a business model perspective, MTD is heavily tied to laboratory and industrial capital expenditure (capex) cycles, meaning its growth trajectory depends on R&D investment trends across pharma, biotech, chemicals, and academia. SYK is more directly levered to healthcare utilization and procedural volumes, which tend to be less discretionary and more demographically driven. On growth drivers, SYK benefits from secular tailwinds including an aging global population, robotic surgery adoption, and ambulatory surgery center expansion. MTD's growth, meanwhile, hinges on innovation in lab automation and an eventual rebound in Chinese demand. Recent momentum has favored SYK, which has posted more consistent earnings beats, while MTD has faced multiple quarters of cautious forward guidance. Risk factors differ as well: MTD carries greater China exposure and currency translation risk, whereas SYK faces regulatory and reimbursement risk across its hospital customer base. Both stocks trade at premium valuations relative to their respective sectors, reflecting quality franchises, though SYK's valuation multiple has been better supported by near-term earnings visibility.
Tickeron AI Verdict
Based on observable trend consistency, relative momentum, and catalyst visibility, Tickeron's AI analytical framework would likely express a near-term preference for SYK over MTD in the current environment. SYK's steadier earnings trajectory, robust procedural volume backdrop, and clearer product-cycle catalysts—particularly around robotic surgery adoption—offer a more favorable configuration for trend-following models. MTD remains a high-quality franchise with strong long-term fundamentals, but its near-term narrative is clouded by lingering demand uncertainty in China and a less visible capex recovery timeline. This AI-informed perspective is probabilistic in nature and reflects current market data rather than a definitive forecast; conditions can shift, and MTD's valuation could become increasingly attractive should macro headwinds begin to fade.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MTD is a Buy and SYK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MTD’s FA Score shows that 2 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- MTD’s FA Score: 2 green, 3 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MTD’s TA Score shows that 6 TA indicator(s) are bullish while SYK’s TA Score has 6 bullish TA indicator(s).
- MTD’s TA Score: 6 bullish, 4 bearish.
- SYK’s TA Score: 6 bullish, 4 bearish.
Price Growth
MTD (@Medical Specialties) experienced а +6.71% price change this week, while SYK (@Medical/Nursing Services) price change was -1.38% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.40%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +6.80%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.50%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -17.67%.
Reported Earning Dates
MTD is expected to report earnings on Nov 05, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical Specialties (+0.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+2.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| MTD | SYK | MTD / SYK | |
| Capitalization | 28.6B | 125B | 23% |
| EBITDA | 1.3B | 6.44B | 20% |
| Gain YTD | 1.586 | -6.833 | -23% |
| P/E Ratio | 31.93 | 37.70 | 85% |
| Revenue | 4.13B | 25.3B | 16% |
| Total Cash | 51.4M | N/A | - |
| Total Debt | 2.11B | 14.7B | 14% |
MTD | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 38 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 98 | 64 | |
SMR RATING 1..100 | 2 | 56 | |
PRICE GROWTH RATING 1..100 | 29 | 53 | |
P/E GROWTH RATING 1..100 | 46 | 82 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (10) in the Medical Specialties industry is significantly better than the same rating for MTD (99). This means that SYK’s stock grew significantly faster than MTD’s over the last 12 months.
SYK's Profit vs Risk Rating (64) in the Medical Specialties industry is somewhat better than the same rating for MTD (98). This means that SYK’s stock grew somewhat faster than MTD’s over the last 12 months.
MTD's SMR Rating (2) in the Medical Specialties industry is somewhat better than the same rating for SYK (56). This means that MTD’s stock grew somewhat faster than SYK’s over the last 12 months.
MTD's Price Growth Rating (29) in the Medical Specialties industry is in the same range as SYK (53). This means that MTD’s stock grew similarly to SYK’s over the last 12 months.
MTD's P/E Growth Rating (46) in the Medical Specialties industry is somewhat better than the same rating for SYK (82). This means that MTD’s stock grew somewhat faster than SYK’s over the last 12 months.
| MTD | SYK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 88% | 4 days ago 34% |
| Stochastic ODDS (%) | 3 days ago 71% | 3 days ago 61% |
| Momentum ODDS (%) | 3 days ago 68% | 3 days ago 51% |
| MACD ODDS (%) | 3 days ago 54% | 3 days ago 73% |
| TrendWeek ODDS (%) | 3 days ago 61% | 3 days ago 52% |
| TrendMonth ODDS (%) | 3 days ago 58% | 3 days ago 47% |
| Advances ODDS (%) | 6 days ago 60% | 5 days ago 56% |
| Declines ODDS (%) | 4 days ago 65% | 3 days ago 52% |
| BollingerBands ODDS (%) | 3 days ago 72% | 3 days ago 63% |
| Aroon ODDS (%) | 3 days ago 55% | 3 days ago 47% |
Advertisement
MTD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MTD has been closely correlated with A. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if MTD jumps, then A could also see price increases.
| Ticker / NAME | Correlation To MTD | 1D Price Change % | ||
|---|---|---|---|---|
| MTD | 100% | +2.59% | ||
| A - MTD | 70% Closely correlated | -0.25% | ||
| TMO - MTD | 67% Closely correlated | -0.43% | ||
| BRKR - MTD | 67% Closely correlated | -2.33% | ||
| AZTA - MTD | 61% Loosely correlated | -2.33% | ||
| RVTY - MTD | 58% Loosely correlated | -0.90% | ||
More | ||||
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.